Toripalimab is a humanized PD-1 monoclonal antibody used to treat nasopharyngeal carcinoma, advanced NSCLC, and advanced esophageal squamous cell carcinoma (Table 1) [52]. Here, PDCD1 is linked to non-small cell lung carcinoma.